-

AgelessRx Launches Methylene Blue, Pioneering Accessible Cognitive Longevity Solutions

New precision-dose solution offers a modern take on a time-tested compound, meeting the rising demand of proactive brain health

ANN ARBOR, Mich.--(BUSINESS WIRE)--AgelessRx, a pioneer in longevity and telehealth solutions, announces the launch of its newest offering: Methylene Blue capsules. Recent studies suggest that Methylene Blue may support focus, brain health, and cellular energy production, all in a mess-free, convenient capsule format.

The launch of Methylene Blue marks AgelessRx’s launch into the cognitive health market valued at $11.55 billion in 2025 and projected to reach $40.27 billion by 2035. The global Methylene Blue market is projected to grow at a 7.3% CAGR through 2032, demonstrating ongoing interest and demand in innovative, preventive health solutions.

By introducing a precision-dosed, purely sourced, stain-free form factor, AgelessRx is expanding access to a promising compound with multiple potential benefits that research is continually uncovering. Methylene Blue marks the company’s third product unveiling in just under four months, demonstrating the brand's commitment to bringing next-generation longevity solutions to market.

“Methylene Blue has stood the test of time, with over 150 years of therapeutic use and is considered one of the first synthetic drugs,” said Dr. Sajad Zalzala, Chief Medical Officer and Co-Founder of AgelessRx. “Today, it’s gaining new relevance as a potential tool for improving cognitive and cellular health. We're proud to help bring this powerful molecule into modern preventive care, further supporting our mission to make longevity accessible for all.”

Research highlights Methylene Blue’s multifaceted potential benefits, including:

  • Cognitive Support & Memory Enhancement: Boosting performance by improving memory, focus, and overall cognitive performance.
  • Mitochondrial Energy Boost: Enhancing mitochondrial efficiency to increase ATP production, which may improve energy while reducing fatigue and brain fog.
  • Anti-inflammatory Support: Stifling inflammatory pathways in the brain to reduce inflammation, which may enhance recovery and slow brain degeneration.
  • Neuroprotection and Healthy Brain Aging: Slowing cognitive decline by improving mitochondrial function and boosting blood flow to the brain.

“Cognitive health is central to quality of life as we age,” shared AgelessRx’s VP of Applied Sciences, Stefanie Morgan. “By targeting and remedying the major hallmarks of brain aging, recent studies suggest that this new offering may represent an important step to mitigate the effects of cognitive decline as we age.”

By offering Methylene Blue in a unique capsulated form, users will benefit from stain-free consumption alongside clinically guided protocols for more precise and personalized dosing supported by expert-led longevity clinicians. As the demand for proactive cognitive care grows, AgelessRx remains committed to delivering clinically validated, science-backed solutions that help millions live better, healthier lives.

For additional information about AgelessRx and its newest offering, Methylene Blue, please visit agelessrx.com.

About AgelessRx

AgelessRx is at the forefront of the longevity revolution, offering clinically validated, cutting-edge solutions and preventive treatments aimed at extending life expectancy and enhancing quality of life. AgelessRx also continues to advance the field of longevity science by conducting ongoing research and clinical trials. Through its online platform, AgelessRx provides easy access to innovative healthcare services, with an emphasis on customer satisfaction, affordability, and the pursuit of a future where extended healthspan is a reality for everyone. Follow AgelessRx on Instagram, X, Facebook, and LinkedIn.

Contacts

Media contact:
JackTaylor PR
agelessrx@jacktaylorpr.com

AgelessRx


Release Versions

Contacts

Media contact:
JackTaylor PR
agelessrx@jacktaylorpr.com

More News From AgelessRx

AgelessRx Expands Offerings to Include Oral GLP-1 Drops to Advance Metabolic Health and Longevity Science

ANN ARBOR, Mich.--(BUSINESS WIRE)--AgelessRx, a pioneer in longevity and telehealth solutions, announced the introduction of oral sublingual drops for GLP-1 receptor agonists Semaglutide and Tirzepatide. By offering non-injectable alternatives to medications that may support metabolic health management1 and counter the effects of aging2, AgelessRx continues to empower individuals to live longer, healthier lives. Optimal metabolic health is a foundational component of longevity. Dysregulated glu...

AgelessRx Enters Sleep Health Category, Underscoring Critical Role Sleep Plays in Healthspan and Lifespan

ANN ARBOR, Mich.--(BUSINESS WIRE)--AgelessRx, a pioneer in longevity and telehealth solutions, today announced its entry into the sleep health category, building on its commitment to redefine aging and improve quality of life. With a strong emphasis on research-backed solutions, AgelessRx’s sleep program provides personalized sleep treatment plans, and two new products–prescription Trazodone and natural, over-the-counter (OTC) Tran-Q Sleep Supplement–alongside easy-to-adopt lifestyle recommenda...

AgelessRx’s PEARL Trial Links Rapamycin Use to Healthspan Improvement

ANN ARBOR, Mich.--(BUSINESS WIRE)--AgelessRx, a leader in longevity telehealth solutions, announced the results of its 12-month, Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) clinical trial, the largest and longest decentralized, crowd-funded trial of its kind on Rapamycin safety for healthy aging in a normative aging population. The double-blind, randomized, placebo-controlled trial is also the first nationwide decentralized trial and the first large-scale intervention...
Back to Newsroom